Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Autor: Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., Knox, J., He, A.R., El-Rayes, B., Acosta-Rivera, M., Lim, H.Y., Soleymani, S., Yao, J., Neely, J., Tschaika, M., Hsu, C., El-Khoueiry, A.B.

Publikováno v: In Annals of Oncology June 2024 35(6):537-548

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.

Autor: Peters S; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch., Paz-Ares LG; Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain. Electronic address: lpazaresr@seom.org., Reck M; Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de., Carbone DP; The Ohio State University Comprehensive Cancer Center and the Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA. Electronic address: David.Carbone@osumc.edu., Brahmer JR; The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Electronic address: brahmju@jhmi.edu., Borghaei H; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: hossein.borghaei@fccc.edu., Lu S; Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China., O'Byrne KJ; Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia. Electronic address: k.obyrne@qut.edu.au., John T; Austin Hospital, Heidelberg, Victoria, Australia. Electronic address: Tom.John@petermac.org., Ciuleanu TE; Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania. Electronic address: tudor_ciuleanu@hotmail.com., Schenker M; SF Nectarie Oncology Center, Craiova, Romania. Electronic address: mike_schenker@yahoo.com., Caro RB; Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain. Electronic address: reyesbernab@gmail.com., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: mnishio@jfcr.or.jp., Cobo M; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. Electronic address: manuelcobodols@yahoo.es., Lee JS; Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: jslee0918@gmail.com., Zurawski B; Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland. Electronic address: bzur1@wp.pl., Pluzanski A; Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Electronic address: adam.pluzanski@coi.pl., Aoyama T; Bristol Myers Squibb, Princeton, NJ, USA. Electronic address: Takekazu.aoyama@bms.com., Tschaika M; Bristol Myers Squibb, Princeton, NJ, USA. Electronic address: Marina.Tschaika@bms.com., Devas V; Bristol Myers Squibb, Princeton, NJ, USA. Electronic address: vipul.devas@bms.com., Grootendorst DJ; Bristol Myers Squibb, Princeton, NJ, USA. Electronic address: Diederik.Grootendorst@bms.com., Ramalingam SS; Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: ssramal@emory.edu.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Oct 04. Date of Electronic Publication: 2024 Oct 04.

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Autor: Schenker M; Sf Nectarie Oncology Center and University of Medicine and Pharmacy, Craiova, Romania., Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile., Richardet M; Fundación Richardet Longo, Instituto Oncológico de Córdoba, Córdoba, Argentina., Ciuleanu TE; Department of Oncology, Oncology Institute Prof Dr Ion Chiricuta, Cluj-Napoca, Romania.; Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schoffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy., Maio M; Department of Oncology, University of Siena and Center for Immuno-Oncology, Siena, Italy., Lugowska I; Department of Early Phase Clinical Trials, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Lupinacci L; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Leary A; Université Paris-Saclay and Institut Gustave‑Roussy, Villejuif, France., Delord JP; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France., Grasselli J; Center for Medical Education and Clinical Research (CEMIC) University Hospital, Buenos Aires, Argentina., Tan DSP; Department of Haematology-Oncology, National University Cancer Institute, Singapore.; Cancer Science Institute, National University of Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore., Friedmann J; Segal Cancer Center, Jewish General Hospital, Montreal, Québec, Canada.; Rossy Cancer Network, McGill University, Montreal, Québec, Canada., Vuky J; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Tschaika M; Bristol Myers Squibb, Princeton, New Jersey, USA., Konduru S; Bristol Myers Squibb, Princeton, New Jersey, USA., Vemula SV; Bristol Myers Squibb, Princeton, New Jersey, USA., Slepetis R; Bristol Myers Squibb, Princeton, New Jersey, USA., Kollia G; Bristol Myers Squibb, Princeton, New Jersey, USA., Pacius M; Bristol Myers Squibb, Princeton, New Jersey, USA., Duong Q; Bristol Myers Squibb, Princeton, New Jersey, USA., Huang N; Bristol Myers Squibb, Princeton, New Jersey, USA., Doshi P; Bristol Myers Squibb, Princeton, New Jersey, USA., Baden J; Bristol Myers Squibb, Princeton, New Jersey, USA., Di Nicola M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy massimo.dinicola@istitutotumori.mi.it.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Aug 06; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 06.

MA11.05 Nivolumab + Ipilimumab vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS

Autor: Wu, Y.-L., Wu, X., Ying, K., Chen, G., Wang, Z., Lin, W., Lu, S., Zhong, H., Cheng, Y., Cui, J., Wang, M., Wang, K., Zhu, B., Yu, X., Chen, Y., Liu, C., Yao, Y., Sun, H., Wang, S., Tschaika, M., Pe Benito, M., Lee, A., Yuan, Y., Wu, L.

Publikováno v: Journal of Thoracic Oncology; October 2024, Vol. 19 Issue: 10, Number 10 Supplement 1 pS97-S98, 2p

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Autor: Yau T; The University of Hong Kong, Hong Kong, China., Zagonel V; Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy., Santoro A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.; IRCCS Humanitas Research Hospital-Humanitas Cancer Center, Rozzano, Italy., Acosta-Rivera M; Fundacion de Investigación, San Juan, Puerto Rico., Choo SP; National Cancer Center and Curie Oncology, Singapore., Matilla A; Servicio de Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Spain.; CIBEREHD, Madrid, Spain., He AR; Georgetown University Hospital, Washington, DC., Cubillo Gracian A; Hospital HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (HM-CIOCC), Madrid, Spain.; Departamento de Ciencias Médicas Clínicas, Universidad Camilo José Cela, Madrid, Spain., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, CA., Sangro B; Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain., Eldawy TE; Sacred Heart Health Systems, Pensacola, FL., Bruix J; BCLC Group, Liver Unit, Hospital Clínic-IDIBAPS, University of Barcelona, CIBEREHD, Barcelona, Spain., Frassineti GL; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Vaccaro GM; Providence Cancer Institute, Portland, OR., Tschaika M; Bristol Myers Squibb, Princeton, NJ., Scheffold C; Exelixis, Inc, Alameda, CA., Koopmans P; Bristol Myers Squibb, Princeton, NJ., Neely J; Bristol Myers Squibb, Princeton, NJ., Piscaglia F; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 20; Vol. 41 (9), pp. 1747-1757. Date of Electronic Publication: 2022 Dec 13.